Assessing Shanghai Henlius Biotech (SEHK:2696) Valuation After China’s Broad HANBEIYOU Approval

Simply Wall St.06-05

Shanghai Henlius Biotech (SEHK:2696) has drawn fresh attention after China’s National Medical Products Administration approved its pertuzumab biosimilar HANBEIYOU for all local reference indications, ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2641449781?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-06-05 22:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2641449781","market":"nz","top_or_hot":-1,"title":"Assessing Shanghai Henlius Biotech (SEHK:2696) Valuation After China’s Broad HANBEIYOU Approval","media":"Simply Wall St.","content":"<div>\n<p>Shanghai Henlius Biotech (SEHK:2696) has drawn fresh attention after China’s National Medical Products Administration approved its pertuzumab biosimilar HANBEIYOU for all local reference indications, ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2696/shanghai-henlius-biotech-shares/news/assessing-shanghai-henlius-biotech-sehk2696-valuation-after-1\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing Shanghai Henlius Biotech (SEHK:2696) Valuation After China’s Broad HANBEIYOU Approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing Shanghai Henlius Biotech (SEHK:2696) Valuation After China’s Broad HANBEIYOU Approval\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-05 22:19 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2696/shanghai-henlius-biotech-shares/news/assessing-shanghai-henlius-biotech-sehk2696-valuation-after-1><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shanghai Henlius Biotech (SEHK:2696) has drawn fresh attention after China’s National Medical Products Administration approved its pertuzumab biosimilar HANBEIYOU for all local reference indications, ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2696/shanghai-henlius-biotech-shares/news/assessing-shanghai-henlius-biotech-sehk2696-valuation-after-1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2696/shanghai-henlius-biotech-shares/news/assessing-shanghai-henlius-biotech-sehk2696-valuation-after-1","article_id":"2641449781","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2696/shanghai-henlius-biotech-shares/news/assessing-shanghai-henlius-biotech-sehk2696-valuation-after-1","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2641449781","pubTimestamp":1780669189,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Shanghai Henlius Biotech (SEHK:2696) has drawn fresh attention after China’s National Medical Products Administration approved its pertuzumab biosimilar HANBEIYOU for all local reference indications, completing a China, US and EU approval set.\nSee our latest analysis for Shanghai Henlius Biotech.\nDespite the HANBEIYOU catalyst and a string of recent trial starts in oncology and immunology, Shanghai Henlius Biotech’s share price has been under pressure in the near term, with the 7 day and 30...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","BK1161":"生物科技","HK0000306701.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) INC","HK0000320223.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) ACC","HK0000320264.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) ACC","BK4581":"高盛持仓","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","02696":"复宏汉霖","XBI":"SPDR S&P Biotech ETF","HK0000306685.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) INC","BK4588":"碎股"},"translate_title":"在中国广泛批准汉北优后评估上海复宏汉霖生物技术（SEHK：2696）的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DCF":1,"XBI":1.5,"02696":0.9},"content_text":"Shanghai Henlius Biotech (SEHK:2696) has drawn fresh attention after China’s National Medical Products Administration approved its pertuzumab biosimilar HANBEIYOU for all local reference indications, completing a China, US and EU approval set. See our latest analysis for Shanghai Henlius Biotech. Despite the HANBEIYOU catalyst and a string of recent trial starts in oncology and immunology, Shanghai Henlius Biotech’s share price has been under pressure in the near term, with the 7 day and 30 day share price returns down 12.12% and 19.95% respectively. At the same time, the 1 year total shareholder return of 32.02% and 3 year total shareholder return of over 4x indicate that longer term momentum has been strong. If you are looking beyond a single biotech and want to see how other health focused AI opportunities are shaping up, this is a good moment to scan the 130 healthcare AI stocks. With the stock down over the past quarter but showing a 32.02% 1 year total return and very large 3 year gains, plus a share price well below some intrinsic estimates, is this a reset that opens a buying window, or is the market already paying a premium for expected future growth? AdvertisementPrice-to-Earnings of 34.2x: Is it justified? Shanghai Henlius Biotech last closed at HK$60.20, and at that price the stock trades on a P/E of 34.2x, which screens as expensive both versus peers and versus an estimated fair P/E of 17.2x. The P/E ratio compares the share price with earnings per share and is a common shorthand for how much investors are paying for each unit of profit. For a profitable biotech with HK$6,666.63m in revenue and HK$827.04m in net income, a higher multiple can reflect expectations about future earnings growth or the strength of its product portfolio. Here, the 34.2x P/E sits above the Asian biotechs industry average of 29.4x and also above the peer average of 26.8x, which points to a clear premium. Compared with the estimated fair P/E of 17.2x, the current level is roughly double what the regression based fair ratio suggests the market could move toward if expectations cooled. Explore the SWS fair ratio for Shanghai Henlius Biotech Result: Price-to-Earnings of 34.2x (OVERVALUED) However, investors still need to watch for execution risk across a broad late stage pipeline, as well as any tighter pricing pressure on oncology biosimilars in core markets. Find out about the key risks to this Shanghai Henlius Biotech narrative. Another View: DCF Suggests A Very Different Story While the 34.2x P/E suggests Shanghai Henlius Biotech is expensive, the SWS DCF model points the other way, with an estimated future cash flow value of HK$177.65 per share versus the current HK$60.20. That implies a wide gap. This raises the question of which signal should matter more to you. Look into how the SWS DCF model arrives at its fair value. 2696 Discounted Cash Flow as at Jun 2026Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Shanghai Henlius Biotech for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 194 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity. Next Steps Curious what to make of this mix of premium valuation signals and supportive DCF work? Use the detailed risk and reward checks to pressure test your own thesis with the 4 key rewards and 1 important warning sign. Looking for more investment ideas? If you want to widen your opportunity set beyond a single biotech, this is a smart time to scan other ideas before the market moves on.  Target reliable income streams by checking stocks in the 492 dividend fortresses that focus on higher yields with support from underlying fundamentals. Hunt for quality at a discount by reviewing the 194 high quality undervalued stocks, where pricing and fundamentals may be out of sync. Strengthen your watchlist with companies from the solid balance sheet and fundamentals stocks screener (408 results) that pair financial resilience with room for future growth.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2641449781","isCrawlerRequest":true}